Abstract:BACKGROUND: Reduced plasma tryptophan occurs in depression and somatization. Induction of indoleamine 2,3-dioxygenase (IDO) with consequent synthesis of tryptophan catabolites (TRYCATs) and lowered tryptophan are associated with the onset of depression in the puerperium and during interferon-alpha treatment. Depression is accompanied by lowered kynurenic acid, a neuroprotectant, or increased kynurenine, a neurotoxic TRYCAT. AIMS AND METHODS: To examine plasma tryptophan; kynurenine; kynurenic acid; the kynurenine / tryptophan (KY/TRP) ratio, indicating IDO activity; and the kynurenine / kynurenic acid (KY/KA) ratio, indicating kynurenine aminotransferase (KAT) activity, in somatization; depression; somatization + depression; and controls. Illness severity is measured by the Somatic Symptom Index (SSI), the Screening for Somatoform Symptoms (SOMS), and the Beck Depression Inventory (BDI). RESULTS: Tryptophan is significantly lower in patients than in controls and lower in somatization than in depression. KY/TRP is significantly increased in somatization. Kynurenic acid is significantly lower in patients than in controls, and lower in somatization than in depression. KY/KA is significantly higher in somatization and somatization + depression than in depression and controls. There are significant correlations between the severity of somatization, but not depression, and KY/TRP and KY/KA (positive) and tryptophan (negative). Kynurenine and kynurenic acid are significantly correlated in controls, somatization + depression, and depression, but not in somatization. CONCLUSIONS: Somatization is characterized by increased IDO activity and disorders in KAT activity and an increased neurotoxic potential. The TRYCAT pathway may play a role in the pathophysiology of somatizing and "psychosomatic" symptoms through effects on pain, gut motility, the autonomic nervous system, peripheral NMDA receptors, etc. Even more, biological disorders, such as aberrations in the TRYCAT pathway, which are considered to be a hallmark for depression, are in fact attributable to somatization rather than to depression per se. Future research in depression on the TRYCAT pathway should always control for the possible effects of somatization.

Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome.

Biological underpinnings of the commonalities in depression, somatization, and Chronic Fatigue Syndrome.

Dysfunction in Serotonergic and Noradrenergic Systems and Somatic Symptoms in Psychiatric Disorders

Inflammatory and Oxidative and Nitrosative Stress Pathways Underpinning Chronic Fatigue, Somatization and Psychosomatic Symptoms

An intriguing and hitherto unexplained co-occurrence: Depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways

In Schizophrenia, Chronic Fatigue Syndrome- and Fibromyalgia-Like Symptoms Are Driven by Breakdown of the Paracellular Pathway with Increased Zonulin and Immune Activation-Associated Neurotoxicity

Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity.

"Functional" or "psychosomatic" Symptoms, E.G. A Flu-Like Malaise, Aches and Pain and Fatigue, Are Major Features of Major and in Particular of Melancholic Depression

Physio-Somatic Symptoms in Schizophrenia: Association with Depression, Anxiety, Neurocognitive Deficits and the Tryptophan Catabolite Pathway

In major dysmood disorder, physiosomatic, chronic fatigue and fibromyalgia symptoms are driven by immune activation and increased immune-associated neurotoxicity

In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation.

Tryptophan catabolites, inflammation, and insulin resistance as determinants of chronic fatigue syndrome and affective symptoms in long COVID

Depression and Sickness Behavior Are Janus-faced Responses to Shared Inflammatory Pathways

Chronic Fatigue Syndrome and Fibromyalgia-Like Symptoms Are an Integral Component of the Phenome of Schizophrenia: Neuro-Immune and Opioid System Correlates

Chronic Fatigue Syndrome: Harvey and Wessely's (bio)psychosocial Model Versus a Bio(psychosocial) Model Based on Inflammatory and Oxidative and Nitrosative Stress Pathways

Psychobiological Aspects of Somatoform Disorders: Contributions of Monoaminergic Transmitter Systems.

The Reification Of The Clinical Diagnosis Of Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (Me/Cfs) As An Immune And Oxidative Stress Disorder: Construction Of A Data-Driven Nomothethic Network And Expo-Sure Of Me/Cfs Subgroups

ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature

Biological mechanisms of somatic symptoms in depressive disorder

Persistent physical symptoms: definition, genesis, and management

Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways